ArticleJCO precision oncology2019
Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer.
Article in JCO precision oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.JCO precision oncology · 2022Pooled it
- Trial
- Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment.NPJ precision oncology · 2025Article
- Bridging the gap: The role of technological advances in shaping gastrointestinal oncological outcomes.World journal of gastrointestinal oncology · 2025Article
- Expert consensus on the optimal management of BRAFAsia-Pacific journal of clinical oncology · 2025Article
- Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors.BJC reports · 2024Article
- Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations.South Asian journal of cancer · 2024Article
- Article
- Current status and perspectives of genetic testing in gastrointestinal cancer (Review).Oncology letters · 2024Review
- The Impact of Molecular Biology in the Seeding, Treatment Choices and Follow-Up of Colorectal Cancer Liver Metastases-A Narrative Review.International journal of molecular sciences · 2023Review
- Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline.Therapeutic advances in medical oncology · 2022Review
- Article
- Review
- Management ofFrontiers in oncology · 2021Review
- Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.Targeted oncology · 2020Review
- Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer.Therapeutic advances in medical oncology · 2020Review
- The evolving treatment paradigm for BRAF V600 mutant colorectal cancer.Annals of translational medicine · 2019Article
- Current and emerging biomarkers in metastatic colorectal cancer.Current oncology (Toronto, Ont.) · 2019Review
- BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.International journal of molecular sciences · 2019Review
- Treatment of extended RAS/PharmacogenomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
purposeAtypical, non-V600 BRAF ( PATIENTS AND
methodsData from 2,084 patients with mCRC at a single institution and from an external cohort of 5,257 circulating tumor DNA (ctDNA) samples were retrospectively analyzed. Overall survival (OS) was calculated using Kaplan-Meier and log-rank tests. Statistical tests were two-sided.
resultsBRAF mutations were harbored by 257 patients, including 36 with
conclusionEfficacy of anti-EGFR therapy is limited in class II and III
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.